GSA Capital Partners’s Axsome Therapeutics AXSM Stock Holding History

GSA Capital Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.31M	Buy	9,419 +7,030	+294%	+$1.52M	0.15%	121
2026 Q1	$404K	Sell	2,389 -6,728	-74%	-$1.16M	0.03%	1051
2025 Q4	$1.67M	Buy	9,117 +4,350	+91%	+$607K	0.14%	142
2025 Q3	$579K	Buy	+4,767	New	+$537K	0.05%	747
2025 Q2	–	Sell	-3,873	Closed	-$452K	–	1744
2025 Q1	$452K	Buy	+3,873	New	+$441K	0.04%	868
2022 Q4	–	Sell	-10,916	Closed	-$487K	–	1458
2022 Q3	$487K	Buy	+10,916	New	+$545K	0.06%	583
2022 Q2	–	Sell	-18,656	Closed	-$772K	–	1399
2022 Q1	$772K	Buy	18,656 +10,699	+134%	+$332K	0.1%	292
2021 Q4	$301K	Buy	+7,957	New	+$293K	0.04%	926
2021 Q3	–	Sell	-9,366	Closed	-$632K	–	1414
2021 Q2	$632K	Buy	+9,366	New	+$562K	0.07%	483

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GSA Capital Partners's AXSM Position: Q2 2026 in Review

GSA Capital Partners increased its Axsome Therapeutics (AXSM) stake by 294% in Q2 2026, buying an estimated $1.52M and bringing the position to 9,419 shares worth $2.31M. The position accounts for 0.15% of the portfolio, ranked #121.

GSA Capital Partners first reported a position in AXSM in Q2 2021 and has held it in 9 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

GSA Capital Partners held 9,419 shares of Axsome Therapeutics worth $2.31M as of Q2 2026.
GSA Capital Partners bought 7,030 Axsome Therapeutics shares in Q2 2026, an estimated $1.52M.
Axsome Therapeutics made up 0.15% of GSA Capital Partners's portfolio in Q2 2026, its #121 holding.
GSA Capital Partners first reported a position in Axsome Therapeutics in Q2 2021 and has held it in 9 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.